Discussions on clinical trial data and real-world experience supporting the use of DUPIXENT in children (6–11) and the psychological burden of AD and how to manage it.
“Experience from two UK centres and implications for treatment in the COVID-19 era”, presented by Professor Carsten Flohr, Dr Hamish Hunter and Dr Richard Woolf.
See what was presented by Dermatologists at the Sanofi-sponsored BAD 2020 symposium, “Clinical experience of DUPIXENT for adults and adolescents with moderate-to-severe AD”.
The clinical implications of Type 2 inflammation in AD, presented at the Clinical Dermatology Update 2020.
DUPIXENT in adolescents with moderate-to-severe AD
Discusses the policies that govern access to dupilumab for adolescents with moderate-to-severe AD in the UK.
Discuss how do you define a ‘moderate’ patient – adult or adolescent?
Discusses the opportunities and challenges of managing adolescent patients with AD.
Discusses the role of a Dermatology nurse in managing and supporting adolescents with moderate-to-severe AD and their carers.
Discusses the pathophysiology of AD and the treatment options for adolescents with moderate-to-severe disease.
Discusses the role of DUPIXENT in the treatment of adolescents with moderate-to-severe AD.
DUPIXENT in adults with moderate-to-severe AD
Discusses AD and the mind.
Discusses the unmet need in AD.
Discusses the pathophysiology of AD and key DUPXIENT trial data.
AD, atopic dermatitis; BAD, British Association of Dermatologists.